Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2018

View Archived Issues

AdAlta redesigns lead candidate for idiopathic pulmonary fibrosis

Biogen and Ionis expand strategic collaboration

IMPACT 1 and IMPACT 2 trial results lead to cadazolid's discontinuation

Clementia begins MO-Ped study of palovarotene

Merck & Co. patents novel mGlu2 receptor negative allosteric modulators

Vanderbilt University describes new WDR5/MLL1 interaction inhibitors

Novel CFTR modulators divulged by Vertex Pharmaceuticals

Sichuan Kelun-Biotech Biopharmaceutical discovers new FXR agonists

EMA grants orphan drug designation for ABO-202 gene therapy program in Batten disease

First efficacy and safety data presented from the RESTORE-IMI 1 phase III trial

Daiichi Sankyo discovers novel proto-oncogene tyrosine-protein kinase receptor Ret inhibitors

Novel calpain inhibitors identified at Blade Therapeutics

Patient enrollment ongoing in phase I study of ANX-007 in primary open-angle glaucoma

Primary endpoint not met in Arpeggio study of laquinimod in primary progressive multiple sclerosis

FDA approves intravenous Akynzeo

Farnesoid X receptor agonist EYP-001 safe and well tolerated in HBV-infected patients

New phase II trial explores GS-9131 functional monotherapy in HIV-1 patients failing NRTI regimen

Fujifilm studies FF-10832 in phase I trial for advanced solid tumors

Lilly reports further data from phase III RANGE study of Cyramza in advanced urothelial carcinoma

GlaxoSmithKline presents novel hSTING agonist GSK-532

FDA clears use of Bruker Maldi Biotyper CA system to identify C. auris

Novartis files for approval of tisagenlecleucel in Japan

Fresenius decides to terminate merger agreement with Akorn

TesoRx conducts pilot study of TSD-001 for low-grade stage Ta non-muscle invasive bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...